Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8842415 | 0.86 | CDK8 (0.56) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL27006451 | 0.84 | LMNA (0.51) | MAPK14KDM4EALDH1A1MAPTPKM | |
| SCHEMBL8842676 | 0.84 | IDO1 (0.42) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL10955444 | 0.82 | P2RX7 (0.42) | MAPK14KDM4EALDH1A1MAPTPKM | |
| SCHEMBL20550826 | 0.79 | MAPK14 (0.54) | MAPK14CSF1RFGFR1FLT1KDR | |
| SCHEMBL8842777 | 0.74 | ADORA2A (0.45) | KDM4EALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10959421 | 0.74 | RXRA (0.42) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL20550958 | 0.73 | KMT2A (0.43) | MAPK14DHODHBCL2L1BADLMNA | |
| SCHEMBL27006410 | 0.72 | NPSR1 (0.45) | KDM4EALDH1A1MAPTPKMPOLB | |
| SCHEMBL20075477 | 0.71 | MAPK14 (0.59) | MAPK14KDRCSNK1A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308558-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| WO-2022193187-A1 | MODULATORS OF FPR1 AND METHODS OF USING SAME | BIOFRONT LTD. (CAYMAN) (KY) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194240-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD. (CAYMAN) (KY) | 2022-09-22 | — | — | WO | disclosed |
| US-5674887-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| EP-0578477-B1 | Treatment of inflammatory bowel disease | LILLY CO ELI (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5436258-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0587378-A1 | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5294630-A | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0578477-A1 | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | MAPK14 1380/4885CSF1R 167/4885FGFR1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.